Hainan Haiyao Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Hainan Haiyao has been growing earnings at an average annual rate of 8.1%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 12.6% per year.
Belangrijke informatie
8.1%
Groei van de winst
8.1%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 10.9% |
Inkomstengroei | -12.6% |
Rendement op eigen vermogen | -20.6% |
Nettomarge | -36.6% |
Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
What Hainan Haiyao Co., Ltd.'s (SZSE:000566) 31% Share Price Gain Is Not Telling You
Oct 25Hainan Haiyao (SZSE:000566) Is Carrying A Fair Bit Of Debt
Oct 06Revenues Not Telling The Story For Hainan Haiyao Co., Ltd. (SZSE:000566)
Sep 09Hainan Haiyao Co., Ltd.'s (SZSE:000566) Shares May Have Run Too Fast Too Soon
Jun 07Investor Optimism Abounds Hainan Haiyao Co., Ltd. (SZSE:000566) But Growth Is Lacking
Feb 26Opbrengsten en kosten
Hoe Hainan Haiyao geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 24 | 1,031 | -377 | 414 | 71 |
30 Jun 24 | 1,112 | -316 | 399 | 59 |
31 Mar 24 | 1,347 | -127 | 451 | 63 |
31 Dec 23 | 1,479 | -106 | 494 | 55 |
30 Sep 23 | 1,557 | 53 | 750 | 49 |
30 Jun 23 | 1,673 | 39 | 803 | 54 |
31 Mar 23 | 1,720 | 33 | 775 | 50 |
01 Jan 23 | 1,779 | 11 | 825 | 49 |
30 Sep 22 | 2,034 | -1,126 | 1,107 | 187 |
30 Jun 22 | 2,094 | -1,197 | 1,187 | 192 |
31 Mar 22 | 2,067 | -1,422 | 1,297 | 197 |
01 Jan 22 | 2,059 | -1,555 | 1,304 | 197 |
30 Sep 21 | 2,038 | -1,097 | 1,444 | 132 |
30 Jun 21 | 2,157 | -1,011 | 1,480 | 131 |
31 Mar 21 | 2,243 | -630 | 1,404 | 129 |
31 Dec 20 | 2,200 | -580 | 1,456 | 126 |
30 Sep 20 | 2,173 | -263 | 1,439 | 124 |
30 Jun 20 | 2,111 | -187 | 1,402 | 107 |
31 Mar 20 | 2,192 | -334 | 1,557 | 102 |
31 Dec 19 | 2,445 | -159 | 1,514 | 92 |
30 Sep 19 | 2,355 | 14 | 1,081 | 15 |
30 Jun 19 | 2,727 | 51 | 1,042 | 18 |
31 Mar 19 | 2,570 | 121 | 1,038 | 19 |
31 Dec 18 | 2,472 | 120 | 1,026 | 19 |
30 Sep 18 | 2,616 | 140 | 1,114 | 45 |
30 Jun 18 | 2,214 | 123 | 1,000 | 43 |
31 Mar 18 | 2,075 | 93 | 749 | 33 |
31 Dec 17 | 1,825 | 87 | 661 | 31 |
30 Sep 17 | 1,753 | 172 | 602 | 4 |
30 Jun 17 | 1,511 | 164 | 572 | 0 |
31 Mar 17 | 1,541 | 172 | 577 | 0 |
31 Dec 16 | 1,509 | 165 | 554 | 0 |
30 Sep 16 | 1,457 | 132 | 424 | 0 |
30 Jun 16 | 1,594 | 196 | 423 | 0 |
31 Mar 16 | 1,649 | 197 | 428 | 0 |
31 Dec 15 | 1,644 | 195 | 423 | 0 |
30 Sep 15 | 1,484 | 226 | 359 | 0 |
30 Jun 15 | 1,428 | 182 | 363 | 0 |
31 Mar 15 | 1,371 | 178 | 352 | 0 |
31 Dec 14 | 1,343 | 163 | 331 | 0 |
30 Sep 14 | 1,264 | 178 | 322 | 0 |
30 Jun 14 | 1,185 | 129 | 317 | 0 |
31 Mar 14 | 1,018 | 96 | 315 | 0 |
31 Dec 13 | 1,018 | 94 | 308 | 0 |
Kwaliteitswinsten: 000566 is currently unprofitable.
Groeiende winstmarge: 000566 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 000566 is unprofitable, but has reduced losses over the past 5 years at a rate of 8.1% per year.
Versnelling van de groei: Unable to compare 000566's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 000566 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).
Rendement op eigen vermogen
Hoge ROE: 000566 has a negative Return on Equity (-20.61%), as it is currently unprofitable.